title: Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine.
abstract: The cytotoxic T lymphocyte (CTL) response was evaluated in adults given live attenuated varicella vaccine, using target cells expressing varicella-zoster virus (VZV) immediate-early protein (IE62) or VZV glycoproteins gpI, gpIV, or gpV to determine viral protein specificity. The frequency of CTL that recognized IE62 was 1:171,000 +/- 46,000 SE in subjects tested 10 days to 8 weeks after the initial vaccine dose; the induction of CTL specific for gpI was equivalent. CTL recognition of VZV proteins was mediated by CD4+ or CD8+ cells. CTL recognition of IE62 and gpIV persisted in vaccinees (tested approximately 4 years later) and was comparable to that in the naturally immune. The mean frequency of CTL specific for gpV was lower (but not significantly) in vaccinees than in naturally immune subjects. Assay of responder cell frequencies showed persistence of equivalent numbers of T lymphocytes that recognized IE62 and gpI in vaccinees and naturally immune subjects. Immunization with this vaccine elicited memory T lymphocyte responses to VZV comparable to those induced by natural infection.
authors.affiliation: Department of Pediatrics, Stanford University School of Medicine, CA 94305.
authors.forename: M
authors.initials: M
authors.lastname: Sharp
authors.forename: K
authors.initials: K
authors.lastname: Terada
authors.forename: A
authors.initials: A
authors.lastname: Wilson
authors.forename: S
authors.initials: S
authors.lastname: Nader
authors.forename: P E
authors.initials: PE
authors.lastname: Kinchington
authors.forename: W T
authors.initials: WT
authors.lastname: Ruyechan
authors.forename: J
authors.initials: J
authors.lastname: Hay
authors.forename: A M
authors.initials: AM
authors.lastname: Arvin
mesh_terms: D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood; D019433:Chickenpox Vaccine; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D017874:Immediate-Early Proteins; D007111:Immunity, Cellular; D007700:Kinetics; D008213:Lymphocyte Activation; D011897:Random Allocation; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D015534:Trans-Activators; D014613:Vaccines, Attenuated / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology; D014764:Viral Proteins / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D019433:Chickenpox Vaccine; C074221:IE62 protein, Human herpesvirus 3; D017874:Immediate-Early Proteins; D015534:Trans-Activators; D014613:Vaccines, Attenuated; D014759:Viral Envelope Proteins; D014764:Viral Proteins; D014765:Viral Vaccines; C056913:glycoprotein E, varicella-zoster virus; C070916:glycoprotein IV, varicella-zoster virus; C070744:glycoprotein V, varicella-zoster virus